The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.
Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.
George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.
The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.
A panel of several of the world’s foremost experts on immunotherapy in lung cancer discuss durvalumab and other emerging approaches for stage III NSCLC.
The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.
Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.
Amid rapid-fire developments in non–small cell lung cancer (NSCLC) research, the role of checkpoint immunotherapy continues to mature.
Karen Reckamp, MD, discusses positive phase III data, recent regulatory approvals, and what research the new year is likely to bring to the field of non-small cell lung cancer (NSCLC).